This page is being served from the Urological Sciences Research Foundation web repository, and was originally posted between 1996-2008. In January 2009 USRF’s founder, Dr. Leonard S. Marks and his staff joined UCLA’s Department of Urology where they are continuing their research. Click for more information.

Breaking News in Urology

April 10, 2000
Abstracted from ABC News Website

by Shawna Vogel


On the Way: Uprima, A 2nd Pill for Impotency

BOSTON, April 10 - Uprima, an impotence pill that works on the brain---a different mechanism than Viagra --- drew a vote of confidence from a federal advisory panel today. The Advisory Committee for Reproductive Health of the Food and Drug Administration voted at a meeting in Bethesda, Md., today to recommend the 2 and 4 milligram doses of Uprima (apomorphine) as a treatment for male erectile dysfunction (impotency). The FDA takes the committee's recommendations into consideration when approving new drugs, but the agency usually follows the advisory panel recommendations. A decision may come in days or in months

Unlike a Viagra pill, which is swallowed, Uprima, or apomorphine is placed under the tongue and absorbed directly into the bloodstream. That means it acts quickly - in as little as 10 minutes, compared to the 20 minutes it takes Viagra to work. Viagra is reviewed extensively on the USRF website.

And Uprima, targets a man's brain instead of his erection equipment the way Viagra does. Viagra works by improving blood flow in the penis. Uprima, once absorbed, is transported to the brain, where it mimics a chemical called dopamine. Having a little extra jolt of dopamine-like Uprima stimulates the parts of the brain that help men become aroused.

Clinical studies have shown that at the 2 milligram dose, about 44 percent of men taking Uprima have success attempting and achieving a firm erection compared to 38 percent for placebo. At higher doses, the success rate goes up to 60 percent. But so does the drug's main side effect - nausea.

"This is a drug which has considerable potential for side effects and that will be dose related," says John Bancroft, director of the Kinsey Institute in Bloomington Indiana. "So it's a question of whether you can get the desired effects at low dose. … I'm cautious, but I think it'll be good to have it."

Uprima is a product of TAP Pharmaceuticals , a joint venture between Takeda Chemical Industries of Japan and Abbott Laboratories.


Molecular Structure of Uprima (apomorphine)

Mechanism of action

Side Effects

A Business Evaluation of Uprima

Uprima abstracts at 2000 AUA Meeting
...and from the 1999 AUA Meeting

Other Impotence Drugs in Development



this is a navigational image map, please load this image to continue.